D1S2.8 150mcl one-inch valve metered dose mental stem aluminum cup inhaler valve

150 mcl refers to 150 microliters, the nominal volume of formulation released per valve actuation. This is determined by the internal geometry of the metering chamber within the valve body. In pharmaceutical aerosol testing, delivered dose uniformity is typically verified using procedures outlined in pharmacopeial standards (such as Ph. Eur. 2.9.18 or USP 601), which measure the mass of active ingredient per actuation across the dose range of the canister.

Metered dose inhaler valves of this category are generally designed for use with hydrofluoroalkane (HFA) propellants — specifically HFA 134a and HFA 227ea — which replaced CFC propellants in pressurized inhalers following the Montreal Protocol. The aluminum cup and metal stem components are chemically compatible with these propellant types. Specific validation testing against the intended formulation is recommended before production deployment.

The primary advantage is dimensional stability over the valve's operational lifespan. A metal stem maintains its cross-sectional geometry under repeated actuation loading, which preserves the valve's interaction with its sealing gaskets and thus maintains dose accuracy over high actuation counts. Plastic stems can experience creep or surface wear that gradually alters the sealing geometry, potentially causing dose variability in later-cycle use — a significant concern in both pharmaceutical and precision laboratory dispensing contexts.

The D1S2.8 uses a one-inch (25.4 mm) valve cup, which is the standard diameter for pressurized MDI aluminum canisters widely used in pharmaceutical inhaler products. This valve cup size is compatible with common canister body diameters including 52 mm and similar formats used in standard pMDI production. The aluminum cup is designed for standard roll-crimping during filling operations. If integrating with non-standard canister sizes, physical fitment testing is advised before production validation.

When used in pharmaceutical MDI applications, this valve type falls under regulatory frameworks governing pressurized inhalation products. Relevant considerations include FDA guidance for pMDI drug products, EU Annex 1 GMP requirements for sterile and aseptic manufacturing contexts, and pharmacopeial aerosol testing methods (Ph. Eur., USP). The valve itself may require extractables and leachables (E&L) testing as part of a complete container closure system study for drug product registration. For non-pharmaceutical laboratory or industrial use, applicable standards will differ based on the jurisdiction and the nature of the dispensed substance.

Uncrimped valves should be stored in sealed packaging in a temperature-controlled environment, typically at or below 25 degrees Celsius with controlled relative humidity. Exposure to humidity extremes can affect the elastomeric gasket components, while elevated temperatures may alter their compression set characteristics. Valves should not be stored in areas with high concentrations of ozone, solvents, or oxidizing agents. Manufacturer-recommended shelf life and storage conditions should be referenced when establishing component handling protocols.